TScan Q2 net loss $24M, cash $208.8M; heme and solid tumor trials advancing

TScan Therapeutics, Inc.

2023-Q2 EPS reported -$1.30 revenue$9,951,000

Net loss of $24.0M in Q2 2023, vs $15.1M in Q2 2022; revenue $3.1M (down from $4.1M).
Ended Q2 2023 with cash $208.8M; raising $134.7M net from June public offering; funded into 2026.
FDA cleared IND for TSC-200-A0201 (HPV16); third solid tumor IND; three TCR-Ts to enter Phase 1 basket study H2 2023.
Heme malignancies: TSC-100/101 at dose level 2, no DLTs; expect RP2D and interim data by end of 2023.
Plans to file INDs for three more TCR-Ts by year-end, including PRAME-targeting TSC-203-A0201.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TScan Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, TScan Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040954

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.